HUP0402022A2 - Szubsztituált fenil-propionsav-származékok mint a humán peroxiszóma proliferátor-aktivált receptor alfa (PPAR) agonistái és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Szubsztituált fenil-propionsav-származékok mint a humán peroxiszóma proliferátor-aktivált receptor alfa (PPAR) agonistái és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0402022A2
HUP0402022A2 HU0402022A HUP0402022A HUP0402022A2 HU P0402022 A2 HUP0402022 A2 HU P0402022A2 HU 0402022 A HU0402022 A HU 0402022A HU P0402022 A HUP0402022 A HU P0402022A HU P0402022 A2 HUP0402022 A2 HU P0402022A2
Authority
HU
Hungary
Prior art keywords
ppar
agonists
pharmaceutical compositions
compositions containing
acid derivatives
Prior art date
Application number
HU0402022A
Other languages
English (en)
Inventor
Eva-Lotte Alstermark Lindstedt
Anna Christina Olsson
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0402022A2 publication Critical patent/HUP0402022A2/hu
Publication of HUP0402022A3 publication Critical patent/HUP0402022A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát képezik az (I) általános képletű vegyületek - aképletben R1 2,4-difluor-fenil- vagy ciklohexil-csoportot jelent - Senantiomerjei, valamint ezek gyógyászatilag alkalmazható sói,szolvátjai (a sók szolvátjait is beleértve), kristályos formái éselőgyógyszer-származékai. A találmány továbbá a fenti vegyületekelőállítására, a vegyületek gyógyszergyártásban való felhasználására,és a vegyületeket tartalmazó gyógyászati készítményekre vonatkozik. Ó
HU0402022A 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) and pharmaceutical compositions containing them HUP0402022A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104334A SE0104334D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005744 WO2003051822A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Publications (2)

Publication Number Publication Date
HUP0402022A2 true HUP0402022A2 (hu) 2005-01-28
HUP0402022A3 HUP0402022A3 (en) 2009-06-29

Family

ID=20286433

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0402022A HUP0402022A3 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) and pharmaceutical compositions containing them
HU0402133A HUP0402133A3 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar), process for their preparation and pharmaceutical compositions containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0402133A HUP0402133A3 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar), process for their preparation and pharmaceutical compositions containing them

Country Status (31)

Country Link
US (2) US7514471B2 (hu)
EP (2) EP1458672B1 (hu)
JP (4) JP3820249B2 (hu)
KR (2) KR20040074094A (hu)
CN (3) CN100406427C (hu)
AR (2) AR038047A1 (hu)
AT (2) ATE363466T1 (hu)
AU (2) AU2002366315A1 (hu)
BR (2) BR0214988A (hu)
CA (2) CA2469302A1 (hu)
CY (2) CY1106276T1 (hu)
DE (2) DE60220441T2 (hu)
DK (2) DK1458672T3 (hu)
ES (2) ES2271381T3 (hu)
HK (2) HK1068604A1 (hu)
HU (2) HUP0402022A3 (hu)
IL (3) IL162331A0 (hu)
IS (2) IS7309A (hu)
MX (2) MXPA04006004A (hu)
MY (1) MY132565A (hu)
NO (2) NO20043023L (hu)
NZ (2) NZ533274A (hu)
PL (2) PL370672A1 (hu)
PT (2) PT1458672E (hu)
RU (2) RU2303031C2 (hu)
SE (1) SE0104334D0 (hu)
SI (2) SI1458672T1 (hu)
TW (2) TWI253444B (hu)
UA (2) UA77987C2 (hu)
WO (2) WO2003051821A1 (hu)
ZA (2) ZA200404658B (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) * 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
BR0311834A (pt) 2002-06-19 2005-04-12 Lilly Co Eli Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
ATE386013T1 (de) 2002-06-20 2008-03-15 Astrazeneca Ab Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1722780A4 (en) * 2003-11-26 2008-12-17 Univ Duke METHOD FOR PREVENTING OR TREATING GLAUCOMA
BRPI0417401A (pt) * 2003-12-15 2007-05-08 Lilly Co Eli composto, composição farmacêutica, métodos para modular um receptor ativado por proliferador de peroxissomo, para tratar doença ou condição, para abaixar glicose sanguìnea em um mamìfero, para tratar diabetes mellitus em um mamìfero, para tratar doença cardiovascular em um mamìfero, para tratar sìndrome x em um mamìfero, e, uso de composto
MX2007001634A (es) * 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
WO2006129164A1 (en) 2005-05-31 2006-12-07 Pfizer Japan Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
TWI331523B (en) * 2005-12-08 2010-10-11 Nat Health Research Institutes Vinylsulfonate compounds
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
JO3301B1 (ar) * 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP2023504645A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
WO2023039276A1 (en) * 2021-09-13 2023-03-16 Curtails Llc Use of ibat inhibitors and antimicrobials for the treatment of diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266121C (hu)
BE489216A (hu) 1948-06-05 1900-01-01
US2928840A (en) * 1958-11-26 1960-03-15 Us Vitamin Pharm Corp 3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en) 1963-09-13 1967-08-31 Stauffer Chemical Co Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) * 1963-10-28 1966-04-05 Scaramucci Domer Composite seat ball valve
AT307640B (de) 1970-06-18 1973-05-25 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr) 1971-12-06 1973-06-06 Basf Ag Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de) 1973-10-01 1985-08-01 Basf Ag, 6700 Ludwigshafen 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de) 1978-06-28 1980-01-10 Bayer Ag Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) * 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US5312924A (en) * 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5216167A (en) * 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5210208A (en) * 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6576766B1 (en) 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
AU760163B2 (en) 1999-04-06 2003-05-08 Sankyo Company Limited Alpha-substituted carboxylic acid derivatives
AU3670900A (en) 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
AU4278400A (en) 1999-04-14 2000-11-14 University Of British Columbia, The Improved beta,beta,-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
WO2002044127A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitué
WO2002044130A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitués
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
WO2002083616A1 (fr) 2001-04-10 2002-10-24 Sankyo Company, Limited DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
BR0311834A (pt) * 2002-06-19 2005-04-12 Lilly Co Eli Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
UA77987C2 (en) 2007-02-15
CN1620422A (zh) 2005-05-25
AU2002366315A1 (en) 2003-06-30
NZ533274A (en) 2005-12-23
PL370672A1 (en) 2005-05-30
IS7309A (is) 2004-06-14
SI1458672T1 (sl) 2007-10-31
IS7313A (is) 2004-06-15
DE60214594D1 (de) 2006-10-19
CN1293044C (zh) 2007-01-03
HUP0402133A3 (en) 2010-07-28
RU2300517C2 (ru) 2007-06-10
JP2006298924A (ja) 2006-11-02
RU2303031C2 (ru) 2007-07-20
EP1458672B1 (en) 2007-05-30
CY1106784T1 (el) 2012-05-23
ZA200404658B (en) 2006-02-22
TWI255807B (en) 2006-06-01
ES2271381T3 (es) 2007-04-16
HUP0402133A2 (hu) 2005-02-28
HK1068870A1 (en) 2005-05-06
IL162330A (en) 2009-06-15
PT1458672E (pt) 2007-07-18
AR038045A1 (es) 2004-12-22
EP1458673A1 (en) 2004-09-22
NO20043023L (no) 2004-07-15
HUP0402022A3 (en) 2009-06-29
UA77460C2 (en) 2006-12-15
RU2004116918A (ru) 2005-11-10
AU2002352427A1 (en) 2003-06-30
CN1620423A (zh) 2005-05-25
KR20040074094A (ko) 2004-08-21
TWI253444B (en) 2006-04-21
TW200410918A (en) 2004-07-01
TW200410925A (en) 2004-07-01
JP2005336209A (ja) 2005-12-08
NZ533276A (en) 2006-04-28
DK1458672T3 (da) 2007-09-17
US7514471B2 (en) 2009-04-07
CA2470491A1 (en) 2003-06-26
US7256307B2 (en) 2007-08-14
ATE338743T1 (de) 2006-09-15
BR0214988A (pt) 2004-12-14
ZA200404657B (en) 2005-08-29
HK1068604A1 (en) 2005-04-29
MY132565A (en) 2007-10-31
DE60214594T2 (de) 2007-09-13
NO20043164L (no) 2004-07-16
EP1458672A1 (en) 2004-09-22
CA2469302A1 (en) 2003-06-26
CY1106276T1 (el) 2011-10-12
RU2004116917A (ru) 2005-11-10
ES2286310T3 (es) 2007-12-01
US20050171204A1 (en) 2005-08-04
SE0104334D0 (sv) 2001-12-19
JP3784804B2 (ja) 2006-06-14
WO2003051822A1 (en) 2003-06-26
AR038047A1 (es) 2004-12-22
EP1458673B1 (en) 2006-09-06
US20050113362A1 (en) 2005-05-26
PL370673A1 (en) 2005-05-30
PT1458673E (pt) 2006-12-29
CN1896045A (zh) 2007-01-17
ATE363466T1 (de) 2007-06-15
WO2003051821A1 (en) 2003-06-26
MXPA04006003A (es) 2004-09-27
CN100406427C (zh) 2008-07-30
JP3820249B2 (ja) 2006-09-13
IL162330A0 (en) 2005-11-20
DE60220441D1 (de) 2007-07-12
DK1458673T3 (da) 2006-12-11
IL162331A0 (en) 2005-11-20
JP2005526704A (ja) 2005-09-08
JP2005526011A (ja) 2005-09-02
SI1458673T1 (sl) 2007-02-28
MXPA04006004A (es) 2004-09-27
BR0214986A (pt) 2004-12-14
KR20040074092A (ko) 2004-08-21
DE60220441T2 (de) 2008-01-24

Similar Documents

Publication Publication Date Title
HUP0402022A2 (hu) Szubsztituált fenil-propionsav-származékok mint a humán peroxiszóma proliferátor-aktivált receptor alfa (PPAR) agonistái és ezeket tartalmazó gyógyszerkészítmények
HUP0102102A2 (hu) Pirazolinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
NZ515705A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
HUP0002347A2 (hu) Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására
NO20085077L (no) Nye forbindelser
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0400636A2 (hu) Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
MA29619B1 (fr) Derive de 1,1 -dioxyde de 1,4-benzothiazepine, procede de preparation, medicaments comprenant ce compose, et utilisation de celui-ci comme hypolipidemiant
NO20090327L (no) Nye forbindelser 384
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
HUP0402616A2 (hu) Bifenilmetil-tiazolidindionok, bifenilpropionsav-származékok, alkalmazásuk PPAR-gamma aktivátorként és az ezeket tartalmazó gyógyszerészeti és kozmetikai készítmények
AR016210A1 (es) Derivador de tienilazolilalcoxietanamina y sus sales fisiologicamente aceptables, procedimientos para obtener dichos derivados, sus enantiomeros puros ydichas sales, las composiciones farmaceuticas que los contienen, el empleo de dichos derivados para la preparacion de medicamentos, los compuestosin
HUP0004427A2 (hu) FP Agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok
NO20040881L (no) Orale antidiabetes midler.
HUP0101498A1 (hu) Dexmedetomidin alkalmazása nyugtató hatású gyógyszerkészítmények előállítására
NO306345B1 (no) Piperidin-derivater med PAF antagonist-aktivitet, anvendelse derav og farmasöytisk blanding
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
ATE89547T1 (de) Dopamin-vorlaeufer.
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HUP0202731A2 (hu) o-Ánizsamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0202803A2 (en) Titanium derived compounds, preparation and use thereof
HUP0203884A2 (hu) Kristályos oximinoalkánsav-származékok és cukorbaj elleni alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények